Venus Remedies has informed that the company achieves a significant milestone with the recent approval of marketing authorizations (MAs) for Enoxaparin 40 mg/0.4 ml and 60 mg/0.6 ml in Azerbaijan, marking the first entry of these products into the country. Enoxaparin Sodium Injection, a low molecular weight heparin, effectively prevents blood clot enlargement and formation, addressing various medical conditions.
The above information is a part of company’s filings submitted to BSE.